Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9623130 | 0.89 | KDM4E (0.33) | ALDH1A1KDM4EL3MBTL1HTT | |
| SCHEMBL20182901 | 0.84 | — | — | |
| SCHEMBL464667 | 0.84 | — | — | |
| SCHEMBL20182898 | 0.84 | — | — | |
| SCHEMBL24456479 | 0.79 | — | — | |
| SCHEMBL24456869 | 0.79 | — | — | |
| SCHEMBL178299 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KDM4EL3MBTL1MAPTHTT | |
| SCHEMBL23583200 | 0.79 | — | — | |
| SCHEMBL20707212 | 0.75 | KDM4E (0.43) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL24456768 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148029-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225477-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023196432-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| WO-2023125708-A1 | P38 MAPK/MK2 PATHWAY MODULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-7271271-B2 | Imidazolo-related compounds, compositions and methods for their use | AMGEN SF, LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2007025284-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | ALDH1A1 4407/4885KDM4E 3314/4885L3MBTL1 4810/4885 |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | ALDH1A1 3576/4885KDM4E 233/4885L3MBTL1 909/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ALDH1A1 135/4885KDM4E 4021/4885L3MBTL1 688/4885 |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | ALDH1A1 89/4885KDM4E 2296/4885L3MBTL1 4471/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | ALDH1A1 1538/4885KDM4E 2994/4885L3MBTL1 183/4885 |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ROCK1, ROCK2, RHOA | ALDH1A1 3878/4885KDM4E 2433/4885L3MBTL1 2529/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | ALDH1A1 1538/4885KDM4E 2994/4885L3MBTL1 183/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | ALDH1A1 4407/4885KDM4E 3314/4885L3MBTL1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.